şizofrenik bozuklukta cinsel işlev bozuklukları - Çukurova Üniversitesi

ABSTRACT
Sexual Dysfunction In Schizophrenia: A Cross-Sectional Evaluation
Objective: In this study, schizophrenic patient group who are regularly tracked in
psychosis unit of Cukurova University Medical School Psychiatry Department are been
investigated in respect to their sexual life. The relation between both applied
pharmacotherapy, sociodemographic data and sexual experiences are being sought, as
well as the link between the applied pharmacotherapy and sexual side effects.
Method: 43 patients who were subject to Diagnostic and Statistical Mental
Disorders-IV diagnostic criteria for Schizophrenic Disorder are monitored by the
Psychotic Disorder Unit and randomly assigned to this study. The data is collected by
the use of Golombok-Rust Sexual Satisfaction Inventory and Designed Patient Registry
Form. Forms are filled through the conversation with patients and their relatives;
policlinic records are also utilized.
Findings: Paricipant patients of the study were % 25,6 female and % 74 male in
gender. Mean age was 42,8±9,95. Average duration of the disorder was 13,2±8,53.
Data obtained from the Golombok-Rust Sexual Satisfaction Inventory indicated
problems in the areas of sexual intercourse frequency in % 77,4 sexual interaction in %
48,8 sexual satisfaction in % 27,9 sexual aversion in % 48,8 and sexual contact in %
4,65 of the patients. Besides, premature ejaculation at a rate of % 84,75 and erectile
dysfunction at a rate of % 75 of the male patient group and vaginusmus in all and
anorgasm at a rate of % 27,3 of the female patient group are identified.
Conclusion: The data acquired through this study resulted in similar outcomes as
with the previously handled ones in this area of interest.
Eventually, in addition to a life-long pattern of illness and social dysfunction in
Schizophrenia, there are a variety of serious problems in sexual functionality due to
both natural course and applied pharmacotherapy. Lack of sexual knowledge in our
society and being undervalued by clinicians are some of the contributing factors to the
problem, as well as the natural course of the illness, features of the pharmacotherapy,
socioeconomic properties. Those factors increase the amount of existing problems,
decrease the quality of life and cause incompliance to drug treatment. Clinicians should
talk to their patients on this topic to pinpoint the source of the problem and minimise
them, to enhance the quality of life and treatment compliance.
Keywords: Antipsychotic, Schizophrenic Disorder, Sexual Dysfunction.
VII